Beam Therapeutics Q2 net loss widens more than expected

Beam Therapeutics

05/08/2025 12:21

Overview

Beam Q2 net loss of $102.3 mln misses analyst expectations, per LSEG data

Operating income for Q2 misses estimates, pretax profit beats, per LSEG data

Beam ends Q2 with $1.2 bln cash, supporting operations into 2028

Outlook

Beam expects BEAM-302 trial data in early 2026

Company plans to present BEACON trial data by end of 2025

Beam plans Phase 1 trial for BEAM-103 by end of 2025

Company expects cash reserves to support operations into 2028

Result Drivers

COSTS - R&D costs increase but General & Administrative (G&A) expenses decline

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 License and Collaboration Revenue
$8.47 mln
Q2 Net Income
Miss
-$102.29 mln
-$95.40 mln (11 Analysts)
Q2 Operating Income
Miss
-$120.15 mln
-$104.80 mln (11 Analysts)
Q2 Pretax Profit
Beat
-$102.29 mln
-$104.90 mln (10 Analysts)
Q2 Operating Expenses
$128.62 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Beam Therapeutics Inc is $41.00, about 53.4% above its August 4 closing price of $19.12

Press Release: ID:nGNX8DNrVk

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)